Kenneth Galbraith
About Kenneth Galbraith
Kenneth Galbraith Company Positions
Kenneth Galbraith currently holds the positions of Chair & CEO and Interim CFO. His leadership spans over 35 years, concentrating on the biotechnology and venture capital sectors. His extensive career includes executive roles along with his participation as a director, investor, and advisor for companies within the biotechnology, medical device, pharmaceutical, and healthcare sectors across North America and the United Kingdom.
Kenneth Galbraith Education and Expertise
Kenneth Galbraith holds a Bachelor of Commerce (Honors) degree from the University of British Columbia, which he earned in 1985. His education has equipped him with essential skills for his extensive career in biotechnology and venture capital sectors. The depth of his knowledge has been critical in guiding companies from early stages through regulatory approval and commercialization.
Kenneth Galbraith's Background in Biotechnology and Venture Capital
Kenneth Galbraith has an extensive background in the biotechnology and venture capital sectors, with over 35 years of experience. Throughout his career, he has contributed significantly to both private and public companies by guiding them from early stages to regulatory approval and commercialization. His roles have spanned from being an executive and director to an investor and advisor.
Kenneth Galbraith Board Membership and Involvement
Kenneth Galbraith is presently a member of the board of directors at Profound Medical. His involvement with this and other companies highlights his continuous contributions to the biotechnology sector, where he provides insights drawn from his vast experience.
Notable Companies Kenneth Galbraith Has Worked With
Kenneth Galbraith has been affiliated with numerous notable biotechnology companies. Some of these include Liminal BioSciences Inc., Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals. His work with these companies spans various critical activities including growth, regulatory approval, and commercialization.